n advisory panel to the World Health Organization (WHO) recently released a statement concluding that it is ethical to use experimental medications and vaccines that have not been formally approved-or even tested in humans-to treat persons with Ebola virus disease in the current West African outbreak (1) . This epidemic has killed more than 2100 persons and has an estimated mortality of 55% to 70% (2, 3) . Thus far, 6 patients have been treated with ZMapp, an investigational, combination monoclonal antibody developed by Mapp Biopharmaceutical. Since receiving treatment, 4 of these patients have improved and 2 have died (3) .
The WHO panel has affirmed the ethical validity of using unapproved medications and has made a concerted attempt to balance the potential benefits of treatment with unknown risks. The panel's position, although specific to the current epidemic, aligns with the expanded access regulations of the U.S. Food and Drug Administration, colloquially known as "compassionate use." These regulations, along with the "animal rule" that governs medications only tested in animal models, are already in place to allow access to unapproved medications in conditions without alternative treatments and include a mandate to monitor and collect data during use (4, 5) . Even before the Ebola crisis, the application of these policies came with logistical and ethical controversy (6) . In the current epidemic setting, the WHO panel mandates 3 ethical norms that raise unique and possibly insurmountable difficulties to providing expanded access: fairness in scarcity, informed consent and respect for the patient, and physician nonmaleficence. In addition, the "celebrity status" of investigational drugs distracts from an at least equally compelling need for standard supportive critical care that is essential in treating Ebola.
Triage in scarce, established treatments is often possible when the natural history of the disease, medication effects, and status of the patient are taken into account. Yet, with experimental treatments, few of these factors can be determined vis-à -vis the effect of the drug-one loses the ability to discern the patients likely to benefit. With this inability to properly triage, the consequences of misuse may be 3-fold: poorer outcomes for the "treated" severely ill population, missed opportunities for realistically treatable patients, and a possible induction of resistance that bears worse outcomes for future patients. The multinational setting of the epidemic magnifies these unknown inequalities. The proprietary nature of unregistered medications amplifies the strain between private supply and public demand. Possible secondary gains demand regulation that can never be attained within the epidemic time frame. These potential difficulties in transitional accountability bring to mind Pfizer's meningococcal meningitis trial, in which 200 Nigerian children were administered dose-reduced ceftriaxone or an unregistered medication, trovafloxacin, without informed consent. This led to a $75 million settlement, international outrage, and 11 deaths, all of which underscore physicians' responsibilities in human research (7) .
Compounding issues raised by scarcity in experimental treatment is the inability of persons in an epidemic to give meaningful informed consent (7). This is multiplied by the likelihood that treating physicians could unknowingly cause harm. Participants consent to early-stage trials-which are done primarily for toxicity and dosing assessment rather than treatment-under the pretext that the trial is a rigorous, stepwise process to benefit future persons (8) . When this paradigm is applied to the epidemic context, problems arise. Data collection is difficult in expanded access and may be impossible during an epidemic (7) . Any data obtained to assess benefit or toxicity could have innumerable biases and misappropriations, making their application under current research standards impossible. The value of informed consent is also diminished because it lacks the pretext of risk acceptance to benefit others. In addition, physicians' ability to meaningfully inform vulnerable populations is overestimated. The belief that informed consent is understood by patients naive to advanced health care, especially in an epidemic, is cavalier (7). It belies participants' perceived risk and physicians' duty to abide by primum non nocere.
These difficulties in the application of expanded access are joined by the misguided attention and funding garnered by unregistered medications and vaccines. Novel treatments can add little to the underfunded areas that are bereft of standard critical care. Combined with public health efforts to stem disease transmission and provide public education, implementing routine hemodynamic support must be the focus of all involved organizations. Without early initiation of supportive care, Ebola can quickly lead to cardiovascular collapse and multiorgan failure (2) . Consequently, an influx of health care personnel adequately supplied with intravenous fluids, catheters, safety needles, and personal protective equipment is the intercession most likely to curb the epidemic.
These interventions must be appropriately directed toward patient treatment and disease containment. Liberia, Guinea, and Sierra Leone have overwhelming infection rates and physician-patient ratios as low as 1 to 100 000 (3, 9) . Case-fatality rates and health care perThis article was published online first at www.annals.org on 14 October 2014.
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© 2015 American College of Physicians 141 sonnel infections are highest and transmission is easiest in areas with overwhelming disease burden and population density (3, 9) . Because thousands more cases are expected, we advocate for focusing experienced personnel and supplies at urban centers within these countries. Priority in these areas should be given to infected health care personnel whose ability to provide future treatment is critical (1) . Next, supportive care should be directed at those with few comorbid conditions and early disease manifestations due to higher rates of recovery and lower rates of transmission to personnel (9) . This strategy ethically stratifies care for affected patients while providing the best chance for epidemic containment.
Moving forward, the medical community must focus on implementing the current standard of care fairly and with maximum benefit while maintaining principled experimentation to provide a better future standard. As more novel medications and vaccines are considered for use, we advocate for a transparent and collaborative effort among all parties supplying and requesting treatments. Confirmation of informed consent by local experts should be required before experimentation, as advised by Nigeria's medical ethics panel (10) . Data and safety monitoring and experimentation protocols, with plans for adequate drug supply to allow sufficiently powered research, must be prospectively provided. And in the end, the application of these policies must come second to providing proven therapy with supportive critical care.
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